It’s time for the Lightning Round. Cramer makes the call on viewer favorites.» Read More
BOTHELL, Wash.-- Drug developer Seattle Genetics Inc. said Tuesday the Food and Drug Administration has accepted its application to market the lymphatic cancer treatment Adcetris for some additional uses. Seattle Genetics expects the FDA to make a decision by Sept. 14.
It’s time for the Lightning Round. Cramer makes the call on viewer favorites.
At least three companies are on the cutting edge of new treatments for perhaps the most feared disease known to mankind.
WASHINGTON, Feb 22- U.S. health regulators approved a new drug made by Swiss drugmaker Roche Holding AG for some patients with late-stage metastatic breast cancer who fail to respond to other therapies.
TheStreet.com suggests stocks that could pop on their earnings reports.
Rock bottom interest rates will likely boost key stocks in the biotechnology sector, but Obamacare will dampen prospects for HMO shares.
TheStreet.com offers up 13 biotech predictions for 2013.